Q32 Bio logo
Q32 Bio
QTTB | NASDAQ
Chart Builder DCF Calculator
$8.29
-$0.42 (-4.82%)
At close: Nov 16, 2026, 4:00 PM ET
$8.29
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Q32 Bio Company Profile

Company profile explained

Company Profile

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

Key Executives

Name Position
Jodie Pope Morrison Chief Executive Officer & Director
Lee H. Kalowski Chief Financial Officer & President
David Appugliese Senior Vice President & Head of People
Elham Hershberger Chief Development Officer
José Trevejo Chief Medical Officer
Maria Marzilli Chief Business Officer
Shelia Violette Co-founder, Chief Scientific Officer & President of Research

Latest SEC Filings

Date Type Title
Oct 28, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 14, 2026 4 Filing
Oct 14, 2026 4 Filing
Oct 14, 2026 4 Filing
Oct 09, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 30, 2026 8-K Current Report
Sep 14, 2026 8-K Current Report
Aug 27, 2026 4 Filing
Aug 27, 2026 4 Filing
Aug 27, 2026 4 Filing
View All SEC Filings ➞
Q32 Bio
Q32 Bio logo
Country United States
IPO Date Mar 28, 2018
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Jodie Pope Morrison

Contact Details

830 Winter Street Waltham, Massachusetts 02451 United States

Stock Details

Ticker Symbol QTTB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001661998
CUSIP Number 746964105
ISIN Number US7469641051
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.